T he Role of E-cadherin / β-catenin C om plex and C yclin D 1 in

Purpose: To determine the relationship between expression pattern of E-cadherin, β-catenin and cyclin D1, and clinicopathologic parameters in patients with head and neck squamous cell carcinomas (HNSCC). Materials and Methods: The authors evaluated the immunohistochemical expression pattern of E-cadherin, β-catenin in relationship with cyclin D1 overexpression, degree of histologic differentiation, clinical stage, and nodal status in 146 head and neck squamous cell carcinomas (HNSCC). The authors also evaluated the expression of E-cadherin/β-catenin complex, E-cadherin/cyclin D1, and β-catenin/cyclin D1 double staining with confocal laser scanning microscope. Results: Aberrant expressions in 78% of E-cadherin, 77% of β-catenin, and 69% of cyclin D1 in the HNSCC were observed. There was correlation of aberrant expression of E-cadherin and nodal status. Cyclin D1 overexpression was also correlated to clinical stage and nodal status. Significant relation was observed between Ecadherin and β-catenin expression patterns. Co-expression of E-cadherin and β-catenin was significantly detected. However, there was no correlation of cyclin D1 overexpression with E-cadherin or β-catenin expression patterns. Conclusion: These results suggest that aberrant expression of E-cadherin, E-cadherin/β-catenin complex, and cyclin D1 may be involved in clinical stage and/or nodal status, and analysis of the pattern of E-cadherin, cyclin D1, and E-cadherin/β-catenin complex may be good prognostic marker of HNSCC. (Cancer Research and Treatment 2004;36:72-78) 󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏 Key W ords: E-cadherin, β-catenin, Cyclin D1, Head and neck squamous cell carcinoma, Prognosis

[1]  T. Amagasa,et al.  Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. , 2003, Oral oncology.

[2]  Jun Yu,et al.  Loss of beta-catenin expression in metastatic gastric cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Gale,et al.  Distribution and prognostic significance of cell cycle proteins in squamous carcinoma of the larynx, hypopharynx and adjacent epithelial hyperplastic lesions , 2003, The Journal of Laryngology & Otology.

[4]  D. Park,et al.  RImmunohistochemical Evaluation of E-cadherin/catenin (alpha-, beta-, gamma-catenin and p120CTN) Complex Expression in Early Gastric Cancer. , 2003, Cancer research and treatment : official journal of Korean Cancer Association.

[5]  K. Cullen,et al.  Molecular biomarkers in HNSCC: prognostic and therapeutic implications , 2001, Expert review of anticancer therapy.

[6]  S. Gansauge,et al.  Reduced membranous and ectopic cytoplasmic expression of β ‐catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer , 2001, International journal of cancer.

[7]  E. Kumpulainen,et al.  Nuclear β catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma , 2001, Journal of clinical pathology.

[8]  M. Hung,et al.  Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[10]  R. Nusse,et al.  Wnt signaling: a common theme in animal development. , 1997, Genes & development.

[11]  P. V. van Diest,et al.  Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.

[12]  J. Schalken,et al.  Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. , 1996, Cancer research.

[13]  W. Wood,et al.  ADJUVANT CHEMOTHERAPY BREAST CANCER PATIENT IN THE NODE-NEGATIVE , 1996 .

[14]  J. Espada,et al.  Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. , 1995, The American journal of pathology.

[15]  S. Hirohashi,et al.  A Truncated β-Catenin Disrupts the Interaction between E-Cadherin and α-Catenin: A Cause of Loss of Intercellular Adhesiveness in Human Cancer Cell Lines , 1994 .

[16]  S. Hirohashi,et al.  c-erbB-2 gene product associates with catenins in human cancer cells. , 1994, Biochemical and biophysical research communications.

[17]  M. Mareel,et al.  Immunohistochemical analysis of E-cadherin expression in human colorectal tumours. , 1993, Pathology, research and practice.

[18]  R. Kemler.  From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. , 1993, Trends in genetics : TIG.

[19]  W. Birchmeier,et al.  Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas. , 1993, Seminars in cancer biology.

[20]  J. Schalken,et al.  Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. , 1993, Cancer research.

[21]  R. Weinberg,et al.  Physical interaction of the retinoblastoma protein with human D cyclins , 1993, Cell.

[22]  P. Jensen,et al.  Regulation of keratinocyte intercellular junction organization and epidermal morphogenesis by E-cadherin , 1992, The Journal of cell biology.

[23]  M. Takeichi,et al.  The 102 kd cadherin-associated protein: Similarity to vinculin and posttranscriptional regulation of expression , 1991, Cell.

[24]  G. Bonadonna,et al.  Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients , 1978, Cancer.

[25]  D. R. Coman.  Adhesiveness and stickiness: two independent properties of the cell surface. , 1961, Cancer research.